483
Azurity Pharmaceuticals, Inc.Azurity Pharmaceuticals, Inc. – FDA 483, Feb 24, 2022
Record Details
An FDA inspection of Azurity Pharmaceuticals, Inc. in Wilmington, MA, identified significant deficiencies across three observations. The firm failed to adequately clean equipment, specifically a sampling booth, and lacked proper sampling procedures for active pharmaceutical ingredients. Additionally, the company did not verify cleaning validation for fill lines after introducing new products, indicating potential risks to drug product quality and purity.
View Company Profile
ID · 2704437d-fff0-4d09-b5aa-59c63a5d39d3
Other documents for Azurity Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.